As mentioned in the literature review, the survival rates of advanced NSCLC patients with the T790M mutation were treated with Osimertinib were 80% at 12 months, 55% at 24 months, and 37% at 36 months.[28] These results indicate that Osimertinib may significantly improve the survival in advanced NSCLC patients with EGFR mutation-positive tumors. Here, EGFR is linked to non-small cell lung carcinoma.